Human Epilepsy Project 3
Public ClinicalTrials.gov record NCT05374928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to make more informed decisions about the factors affecting their quality of life, including plans for driving, relationships, pregnancy, schooling, work, and play. In addition to its impact on clinical care, the data and specimens collected in HEP3, including sequential electrophysiology, biochemical profiles and neuroimaging and banked DNA for future genomics studies, have the potential to provide new insights into the biological basis of IGE, thereby advancing the discovery of effective treatments and cures. By enrolling both newly diagnosed subjects (prognosis unknown) as well as subjects with established IGE who are already determined to be treatment resistant or treatment responsive, the study team can immediately test potential biomarkers in a confirmation cohort, which will accelerate identification of predictive biomarkers.
Study identification
- NCT ID
- NCT05374928
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 316 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2020
- Primary completion
- Dec 30, 2025
- Completion
- May 31, 2026
- Last update posted
- Jun 21, 2026
2020 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco (UCSF) | San Francisco | California | 94143 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20057 | — |
| University of Miami | Miami | Florida | 33146 | — |
| Maine Medical Center | Portland | Maine | 04102 | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Mid-Atlantic Epilepsy Sleep Center | Bethesda | Maryland | 20817 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Minnesota Epilepsy Group | Saint Paul | Minnesota | 55113 | — |
| Washington University | St Louis | Missouri | 63130 | — |
| St. Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| NYU Langone Health - Comprehensive Epilepsy Center (CEC) | New York | New York | 10016 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Northwell Health | New York | New York | 10065 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Texas Health Science Center | San Antonio | Texas | 77030 | — |
| University of Utah Hospital | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05374928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05374928 live on ClinicalTrials.gov.